Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in the 2021 Jefferies London Healthcare Conference. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 8:00 am GMT (3:00 am ET) on Thursd

Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the third quarter ended September 30, 2021.“The past several months have been quite productive for Sierra with the addition of SRA515 to our pipeline and preparing for momelotinib pivotal data,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Offic

Sierra Oncology Reports Third Quarter 2021 Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting being held virtually and in Atlanta, GA December 11-14, 2021. Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Re

Sierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASH

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life

Sierra Oncology to Present at Three September Investor Conferences

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food &

Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding

AstraZeneca

Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode.  Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022.

Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the second quarter ended June 30, 2021. “We are extremely excited by the progress that has been made in the second quarter with the completion of enrollment for our MOMENTUM study,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer at Sierra

Sierra Oncology Reports Second Quarter 2021 Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial

For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier times ahead, which will allow investors to take calls on the company's stock with far greater confidence, possibly after SRRA's ongoing Phase 3 trial results.

Sierra Oncology: Time To Enter For The Big Pie

- Ms. Thomson brings extensive strategic, transactional and intellectual property experience as Sierra prepares for potential transition into a commercial company -

Sierra Oncology Appoints Christina Thomson as General Counsel

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?

Sierra Oncology, Inc. (SRRA) Nick Glover on Q4 2019 Results - Earnings Call Transcript

Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Why Earnings Season Could Be Great for Sierra Oncology (SRRA)

Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.

News for Sierra Oncology Stock (SRRA)